美国慢性胰腺炎与胰腺癌患者胰酶替代治疗使用不足且不规范
结果显示检测率与足量PERT处方率均很低,慢性胰腺炎中仅6.5%接受检测、8.5%获足量处方,胰腺癌中仅1.9%接受检测、5.5%获足量处方,提示临床实践与指南存在差距。
要点
- 慢性胰腺炎患者中仅6.5%接受外分泌功能不全检测,8.5%获足量PERT处方。
- 胰腺癌患者中仅1.9%接受检测,5.5%获足量PERT处方。
- 共病数量、检测、胰腺手术和入组时长可预测PERT使用及足量处方。
核心结论
- 在美国参保人群中,慢性胰腺炎或胰腺癌患者的外分泌功能不全检测及足量PERT使用不频繁且不一致。
研究设计与样本
- 利用覆盖美国80余个医疗计划、代表48.67百万人的全国代表性行政数据库进行回顾性分析。
主要发现
- 慢性胰腺炎患者中6.5%接受过外分泌功能不全检测,30.4%填写过PERT处方,8.5%获足量处方。
- 胰腺癌患者中1.9%接受过检测,21.9%填写过PERT处方,5.5%获足量处方。
- 共病数量、外分泌功能不全检测、胰腺手术和入组时长是PERT使用及足量处方的独立预测因素。
临床怎么用
- 对慢性胰腺炎和胰腺癌患者应提高外分泌功能不全的检测意识。
- 需针对共病多、未手术等低预测因素患者加强PERT规范使用教育。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with chronic pancreatitis or pancreatic cancer commonly develop exocrine pancreatic insufficiency, and may not be adequately treated with pancreatic enzyme replacement therapy (PERT). AIMS: To estimate the frequency of diagnostic testing for exocrine insufficiency, and appropriate use of PERT, in a commercially insured population in the US. METHODS: We utilised a nationally representative administrative database representing 48.67 million individuals in over 80 US healthcare plans to assess testing for and treatment of exocrine insufficiency in patients who received a diagnosis of chronic pancreatitis (n = 37 061) or pancreatic cancer (n = 32 461) from 2001 to 2013. We identified the details of any testing for exocrine insufficiency and PERT use. We defined appropriate PERT use as a dosage of ≥120 000 USP units of lipase daily. Multiple logistic regression was used to identify predictors of appropriate use of PERT. RESULTS: In patients with chronic pancreatitis, 6.5% had any testing for exocrine insufficiency, 30.4% filled a prescription for PERT, and 8.5% were prescribed an adequate dose. In those with pancreatic cancer, 1.9% had testing for exocrine insufficiency, 21.9% filled a prescription for PERT, and 5.5% were prescribed an adequate dose. Number of comorbidities, testing for exocrine insufficiency, pancreatic surgery and duration of enrolment were independent predictors for use and appropriate dosing. CONCLUSIONS: Testing for exocrine insufficiency, and appropriate dosing of PERT in patients with chronic pancreatitis or pancreatic cancer, is infrequent and inconsistent in an insured US population. Efforts are needed to educate medical providers on the best practices for managing exocrine pancreatic insufficiency in these patients.
引用
- Forsmark CE, Tang G, Xu H, et al. The use of pancreatic enzyme replacement therapy in patients with a diagnosis of chronic pancreatitis and pancreatic cancer in the US is infrequent and inconsistent. Aliment Pharmacol Ther. 2020. PMID: 32249970. doi:10.1111/apt.15698
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。